Canada’s Drug Agency (CDA-AMC) recommends that Bylvay be reimbursed by public drug plans for the treatment of cholestatic pruritus in patients aged 12 months and older with Alagille syndrome (ALGS), if certain conditions are met.
Canada’s Drug Agency (CDA-AMC) recommends that Bylvay be reimbursed by public drug plans for the treatment of cholestatic pruritus in patients aged 12 months and older with Alagille syndrome (ALGS), if certain conditions are met.